Synopsis A novel clinical trial demonstrated that intratympanic dexamethasone (ITD) therapy may have better improvements of tinnitus and hearing gains at 8 KHz than hyperbaric oxygen (HBO) therapy in patients with refractory high-frequency sudden sensorineural hearing loss (SSNHL) after the failure of conventional therapy. This week's 'MED FACT' discusses a clinical trial from American journal of otolaryngology, “ Comparison of intratympanic dexamethasone therapy and hyperbaric oxygen therapy for the salvage treatment of refractory high-frequency sudden sensorineural hearing loss ”. June 2018.
Authors : Sun H; Qiu X; Hu J; Ma Z. Key Takeaways Intratympanic dexamethasone therapy improves tinnitus and hearing gains in a better way than hyperbaric oxygen therapy. Objective Study Type Participants To compare the efficacy of intratympanic dexamethasone (ITD) therapy with hyperbaric oxygen…
